Zantac
In October 2019, a class-action lawsuit was filed against Sanofi for allegedly misleadingly marketing the over-the-counter heartburn medication Zantac as safe when, according to plaintiffs, the medicine contains dangerously high levels of the carcinogen N-nitrosodimethylamine (NDMA). (Rodriguez et al v. Sanofi U.S. LLC et al, Case No. 19-cv-9527, S. D. NY.)
Class-Action Tracker
The Latest
How Ethos Sold Wall Street on AI While Powering an Analog Boiler Room
Jenny Ahn, Michelle Cera, Ruth Reader, Hunterbrook
CATrends: Unscented Deodorants and Antiperspirants
Lawsuits allege marketing doesn’t pass the smell test.
HydroJug’s Heat-Retention Claims
Can these bottles really keep drinks hot for up to six hours?
With Personalized Pricing, Disclosure Is a Start, But Not a Finish Line
TINA.org and other consumer advocates file comment with FTC.
MLMs Are Consistently Leaving Participants Behind
New book explores why MLMs are often associated with harmful outcomes – and what can be done about it.